Literature DB >> 15246845

Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.

Sultan Darvesh1, Rakesh C Arora, Earl Martin, David Magee, David A Hopkins, J Andrew Armour.   

Abstract

Cholinesterase inhibitors used to treat the symptoms of Alzheimer's disease (AD) inhibit both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), albeit to different degrees. Because central and peripheral neurons, including intrinsic cardiac neurons located on the surface of the mammalian heart, express both BuChE and AChE, we studied spontaneously active intrinsic cardiac neurons in the pig as a model to assess the effects of inhibition of AChE compared to BuChE. Neuroanatomical experiments showed that some porcine intrinsic cardiac neurons expressed AChE and/or BuChE. Enzyme kinetic experiments with cholinesterase inhibitors, namely, donepezil, galantamine, (+/-) huperzine A, metrifonate, rivastigmine, and tetrahydroaminoacridine, demonstrated that these compounds differentially inhibited porcine AChE and BuChE. Donepezil and (+/-) huperzine A were better reversible inhibitors of AChE, and galantamine equally inhibited both the enzymes. Tetrahydroaminoacridine was a better reversible inhibitor of BuChE. Rivastigmine caused more rapid inactivation of BuChE as compared to AChE. Neurophysiological studies showed that acetylcholine and butyrylcholine increase or decrease the spontaneous activity of the intrinsic cardiac neurons. Donepezil, galantamine, (+/-) huperzine A, and tetrahydroaminoacridine changed spontaneous neuronal activity by about 30-35 impulses per minute, while rivastigmine changed it by approximately 100 impulses per minute. It is concluded that (i) inhibition of AChE and BuChE directly affects the porcine intrinsic cardiac nervous system, (ii) the intrinsic cardiac nervous system represents a suitable model for examining the effects of cholinesterase inhibitors on mammalian neurons in vivo, and (iii) the activity of intrinsic cardiac neurons may be affected by pharmacological agents that inhibit cholinesterases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15246845     DOI: 10.1016/j.expneurol.2004.05.002

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  7 in total

1.  Donepezil-associated bradyarrhythmia in a patient with dementia with Lewy bodies (DLB).

Authors:  Michael H Rosenbloom; Richard Finley; Melvin M Scheinman; Mitchell D Feldman; Bruce L Miller; Gil D Rabinovici
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Apr-Jun       Impact factor: 2.703

Review 2.  Muscarinic receptors and ligands in cancer.

Authors:  Nirish Shah; Sandeep Khurana; Kunrong Cheng; Jean-Pierre Raufman
Journal:  Am J Physiol Cell Physiol       Date:  2008-11-26       Impact factor: 4.249

Review 3.  Cholinesterases and the fine line between poison and remedy.

Authors:  Carey N Pope; Stephen Brimijoin
Journal:  Biochem Pharmacol       Date:  2018-01-31       Impact factor: 5.858

4.  Alterations of serum cholinesterase in patients with gastric cancer.

Authors:  Shan-Zhi Gu; Xin-Han Zhao; Ping Quan; Sheng-Bin Li; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

Review 5.  A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies-Emphasis on Alzheimer's Disease Pathogenesis.

Authors:  Mayuri Shukla; Prapimpun Wongchitrat; Piyarat Govitrapong
Journal:  Neurochem Res       Date:  2022-02-05       Impact factor: 3.996

6.  Effectiveness of donepezil, rivastigmine, and (+/-)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine.

Authors:  Yasco Aracava; Edna F R Pereira; Miriam Akkerman; Michael Adler; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2009-09-09       Impact factor: 4.030

7.  Association Between Cholinesterase Inhibitors and New-Onset Heart Failure in Patients With Alzheimer's Disease: A Nationwide Propensity Score Matching Study.

Authors:  Ming-Jer Hsieh; Dong-Yi Chen; Cheng-Hung Lee; Chia-Ling Wu; Ying-Jen Chen; Yu-Tung Huang; Shang-Hung Chang
Journal:  Front Cardiovasc Med       Date:  2022-03-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.